來源紀錄
A weekly glucose-pattern note for the diabetes visit
示意性醫院
此語言的正文尚未翻譯，暫以英文顯示。
This source is an illustrative composite written by Madical AI Use on 14 September 2026. It is not a glucose-outcome study and it quotes no time-in-range result, hypoglycemia rate, or insulin-dose change. It describes a clinician-edited summary of a continuous-glucose export. The ADA Standards of Care are cited only because they already discuss glucose-monitoring metrics. FDA’s artificial-pancreas materials are cited to mark closed-loop systems as a separate regulated class.
- 來源日期
- 2026年9月14日 · 年份 2026
- 證據標籤
- 示意性
- 來源類型
- 醫院
完整引用
Illustrative composite, Madical AI Use
Madical AI Use. Illustrative composite: a weekly glucose-pattern note for the diabetes visit. Index entry dated 14 September 2026. Not a peer-reviewed paper or a device study.
已公開的關鍵事實
- The draft is built from a continuous-glucose export the clinic already receives.
- The note may mention time in range, overnight lows, and days that look different. Those phrases describe the file. They are not measured outcomes of this composite.
- The clinician edits the draft and decides any insulin change.
- Autonomous dosing is excluded.
- Closed-loop insulin systems are separate regulated devices and are not this workflow.
構造本情境時使用的參考文獻
- American Diabetes Association. Standards of Care in Diabetes. Cited for the existence of public glucose-monitoring guidance, not as a result of this composite.
- U.S. Food and Drug Administration. Artificial pancreas device systems. Cited to mark automated insulin delivery as a separate regulated class.
供教育和市場掃描的目錄條目。不是醫療建議，也不是背書。